Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation
The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk facto...
Saved in:
Published in | Frontiers in immunology Vol. 13; p. 1081942 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
13.12.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 1664-3224 1664-3224 |
DOI | 10.3389/fimmu.2022.1081942 |
Cover
Abstract | The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.
We included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.
In our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.
TMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA. |
---|---|
AbstractList | ObjectiveThe pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.MethodsWe included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.ResultsIn our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.ConclusionsTMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA. The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts. We included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy. In our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues. TMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA. The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.ObjectiveThe pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.We included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.MethodsWe included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.In our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.ResultsIn our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.TMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA.ConclusionsTMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA. |
Author | Zhang, Binshan Xing, Guolan |
AuthorAffiliation | Department of nephrology, First Affiliated Hospital of Zhengzhou University , Zhengzhou , China |
AuthorAffiliation_xml | – name: Department of nephrology, First Affiliated Hospital of Zhengzhou University , Zhengzhou , China |
Author_xml | – sequence: 1 givenname: Binshan surname: Zhang fullname: Zhang, Binshan – sequence: 2 givenname: Guolan surname: Xing fullname: Xing, Guolan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36582241$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kj1vHCEQhleRo9hx_AdSRJRp7sLXstBEiqx8WLKUxqnRwLJ3WLuwAfYil_nn4T5i2SlCA5p55xlg3tfNWYjBNc1bgteMSfVh8NO0rCmmdE2wJIrTF80FEYKvGKX87Mn5vLnK-R7XxRVjrH3VnDPRypohF83vu22Kk4nFWzR5myKEjY8zlO0DmlzvobiM5hgTmlPchJh9RjDFsEHjMi8ZBTdvky81uvOAbJzm0U0uFDQ6W3xAEHoEY3EpQPE7h_bkX_CAoGZ3NRTDm-blAGN2V6f9svnx5fPd9bfV7fevN9efbleWKVlWknR0oK3rLfTOCsM4o8ZINvRdLwwWrueYGEsJk5wSKjFRyjEiWxCq5R1hl83NkdtHuNdz8hOkBx3B60Mgpo2GVL9hdBosFlyBIgITTlsqBeXMmIFbYyq3r6yPR9a8mPpLtj44wfgM-jwT_FZv4k6rTlHV4Qp4fwKk-HNxuejJZ-vGEYKLS9a0a5VqOyr20ndPez02-TvDKqBHQZ1ezskNjxKC9d4r-uAVvfeKPnmlFsl_iqwvh3nU-_rxf6V_AClIyMA |
CitedBy_id | crossref_primary_10_1093_ckj_sfae212 crossref_primary_10_1146_annurev_med_042921_102405 crossref_primary_10_1007_s11255_023_03715_w crossref_primary_10_1016_j_clim_2023_109735 crossref_primary_10_3389_fimmu_2024_1453030 crossref_primary_10_1007_s13730_025_00978_3 crossref_primary_10_3390_ijms25168981 crossref_primary_10_47360_1995_4484_2024_55_64 crossref_primary_10_1177_23247096251316364 crossref_primary_10_1136_lupus_2023_000996 |
Cites_doi | 10.1111/cei.13497 10.1002/art.1780350606 10.1136/ard-2022-223035 10.1073/pnas.1202588109 10.1056/NEJMra1312353 10.1016/j.kint.2021.05.021 10.2215/cjn.00620117 10.1056/NEJMra1100359 10.1053/j.ackd.2019.10.003 10.1038/s41584-020-0401-9 10.1016/j.humimm.2013.04.030 10.3389/fimmu.2016.00055 10.1016/j.trsl.2022.03.005 10.3899/jrheum.141163 10.1146/annurev-med-061813-013241 10.1056/NEJMoa2023386 10.1016/j.biopha.2022.113433 10.1681/asn.2014050429 10.1056/nejm200104053441406 10.1007/s11033-011-1361-6 10.1177/0961203311422093 10.1681/asn.V481499 10.1002/art.40930 10.1038/srep31877 10.1007/s10067-020-05499-1 10.1016/j.autrev.2022.103072 10.1016/j.kint.2017.11.023 10.1681/asn.2005080868 10.3389/fimmu.2021.654652 10.1186/s12882-020-01888-5 10.1186/ar4142 10.1681/asn.2010060647 10.1038/nrneph.2012.195 10.1016/j.molimm.2014.06.030 10.1084/jem.20090633 10.1191/0961203305lu2238oa 10.1038/s41584-021-00739-3 10.4049/jimmunol.1501717 10.1681/asn.2013010026 10.1177/0961203310368409 10.4049/jimmunol.164.2.786 10.1038/ki.2012.409 10.1111/j.1523-1755.2004.00371.x 10.3899/jrheum.180773 10.1177/0961203310376523 10.1182/bloodadvances.2018019596 10.1016/s0272-6386(12)80885-7 10.1177/0961203311415561 10.2215/cjn.06230614 10.1038/nrneph.2012.141 10.1038/nrneph.2017.85 10.1182/blood-2016-10-709857 10.1080/0886022x.2019.1702057 10.1016/0002-9343(83)90338-8 10.1097/00005792-199709000-00003 10.3389/fimmu.2021.690821 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Zhang and Xing. Copyright © 2022 Zhang and Xing 2022 Zhang and Xing |
Copyright_xml | – notice: Copyright © 2022 Zhang and Xing. – notice: Copyright © 2022 Zhang and Xing 2022 Zhang and Xing |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.3389/fimmu.2022.1081942 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_ac0649a91601425286243bbf4cbb019d PMC9792970 36582241 10_3389_fimmu_2022_1081942 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c398t-8172f25edcadec6b3432bb83fd7d6b06ed401bc2138421280199e3185a6954713 |
IEDL.DBID | M48 |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:27:07 EDT 2025 Thu Aug 21 18:40:20 EDT 2025 Thu Sep 04 21:55:57 EDT 2025 Thu Jan 02 22:53:15 EST 2025 Thu Apr 24 23:03:33 EDT 2025 Tue Jul 01 02:13:31 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | alternative pathway lupus nephritis thrombotic microangiopathy complement lectin pathway |
Language | English |
License | Copyright © 2022 Zhang and Xing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c398t-8172f25edcadec6b3432bb83fd7d6b06ed401bc2138421280199e3185a6954713 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Dong-Qing Ye, Anhui Medical University, China Reviewed by: Masaru Kato, Hokkaido University, Japan; Koshy Nithin Thomas, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGI), India This article was submitted to Autoimmune and Autoinflammatory Disorders: Autoimmune Disorders, a section of the journal Frontiers in Immunology |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2022.1081942 |
PMID | 36582241 |
PQID | 2759957260 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ac0649a91601425286243bbf4cbb019d pubmedcentral_primary_oai_pubmedcentral_nih_gov_9792970 proquest_miscellaneous_2759957260 pubmed_primary_36582241 crossref_primary_10_3389_fimmu_2022_1081942 crossref_citationtrail_10_3389_fimmu_2022_1081942 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-12-13 |
PublicationDateYYYYMMDD | 2022-12-13 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-13 day: 13 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Tian (B2) 2022 Kaplan (B54) 2002; 3 Dobó (B13) 2016; 6 Austin (B30) 1983; 75 Park (B49) 2018; 2 Chen (B56) 2022; 153 Bombardier (B24) 1992; 35 Brocklebank (B33) 2018; 13 (B26) 2021; 100 Scheen (B39) 2022; 21 Zheng (B51) 2015; 66 Song (B7) 2013; 15 Gregersen (B1) 2012; 8 Macedo (B10) 2016; 7 Shen (B47) 2010; 19 Wright (B53) 2020; 21 Bao (B45) 2011; 22 Józsi (B36) 2006; 17 Lee (B18) 2012; 39 Wu (B6) 2013; 83 George (B8) 2014; 371 Elhadad (B19) 2021; 203 Watanabe (B44) 2000; 164 Jayne (B55) 2021; 384 Lech (B9) 2013; 24 Nisihara (B17) 2013; 74 Maria (B3) 2020; 16 Oroszlán (B14) 2016; 196 Parra Sánchez (B52) 2022; 18 Banfi (B35) 1991; 18 Walport (B27) 2001; 344 Ding (B25) 2020; 42 Joly (B50) 2017; 129 Mejia-Vilet (B40) 2021; 40 Mathern (B15) 2015; 10 Hu (B34) 2010; 19 Aringer (B22) 2019; 71 Chua (B48) 2015; 26 Thurman (B12) 2020; 27 Sato (B42) 2011; 20 Descombes (B29) 1997; 76 Elliott (B20) 2004; 65 Héja (B11) 2012; 109 Grumach (B37) 2014; 61 Noris (B21) 2012; 8 Li (B28) 2019; 46 Aradottir (B57) 2021; 12 Ding (B32) 2021; 12 Yu (B38) 2017; 13 Takahashi (B43) 2010; 207 Appel (B5) 1994; 4 Contreras (B31) 2005; 14 Satyam (B16) 2022; 245 Troldborg (B41) 2015; 42 Tsokos (B4) 2011; 365 Bajema (B23) 2018; 93 Batal (B46) 2012; 21 |
References_xml | – volume: 203 start-page: 96 year: 2021 ident: B19 article-title: Masp2 levels are elevated in thrombotic microangiopathies: Association with microvascular endothelial cell injury and suppression by anti-Masp2 antibody narsoplimab publication-title: Clin Exp Immunol doi: 10.1111/cei.13497 – volume: 35 year: 1992 ident: B24 article-title: Derivation of the sledai. a disease activity index for lupus patients. the committee on prognosis studies in sle publication-title: Arthritis Rheum doi: 10.1002/art.1780350606 – year: 2022 ident: B2 article-title: Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study publication-title: Ann Rheum Dis doi: 10.1136/ard-2022-223035 – volume: 109 year: 2012 ident: B11 article-title: Revised mechanism of complement lectin-pathway activation revealing the role of serine protease masp-1 as the exclusive activator of masp-2 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1202588109 – volume: 371 year: 2014 ident: B8 article-title: Syndromes of thrombotic microangiopathy publication-title: N Engl J Med doi: 10.1056/NEJMra1312353 – volume: 100 start-page: S1 year: 2021 ident: B26 article-title: Clinical practice guideline for the management of glomerular diseases publication-title: Kidney Int doi: 10.1016/j.kint.2021.05.021 – volume: 13 year: 2018 ident: B33 article-title: Thrombotic microangiopathy and the kidney publication-title: Clin J Am Soc Nephrol doi: 10.2215/cjn.00620117 – volume: 365 year: 2011 ident: B4 article-title: Systemic lupus erythematosus publication-title: N Engl J Med doi: 10.1056/NEJMra1100359 – volume: 27 start-page: 86 year: 2020 ident: B12 article-title: Complement and the kidney: An overview publication-title: Adv Chronic Kidney Dis doi: 10.1053/j.ackd.2019.10.003 – volume: 16 year: 2020 ident: B3 article-title: Protecting the kidney in systemic lupus erythematosus: From diagnosis to therapy publication-title: Nat Rev Rheum doi: 10.1038/s41584-020-0401-9 – volume: 74 year: 2013 ident: B17 article-title: Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients publication-title: Hum Immunol doi: 10.1016/j.humimm.2013.04.030 – volume: 7 year: 2016 ident: B10 article-title: Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway publication-title: Front Immunol doi: 10.3389/fimmu.2016.00055 – volume: 245 year: 2022 ident: B16 article-title: Intertwined pathways of complement activation command the pathogenesis of lupus nephritis publication-title: Transl Res doi: 10.1016/j.trsl.2022.03.005 – volume: 42 year: 2015 ident: B41 article-title: Levels in plasma of the serine proteases and associated proteins of the lectin pathway are altered in patients with systemic lupus erythematosus publication-title: J Rheum doi: 10.3899/jrheum.141163 – volume: 66 year: 2015 ident: B51 article-title: Adamts13 and Von willebrand factor in thrombotic thrombocytopenic purpura publication-title: Annu Rev Med doi: 10.1146/annurev-med-061813-013241 – volume: 384 start-page: 599 year: 2021 ident: B55 article-title: Avacopan for the treatment of anca-associated vasculitis publication-title: N Engl J Med doi: 10.1056/NEJMoa2023386 – volume: 153 year: 2022 ident: B56 article-title: Complement factor b inhibitor Lnp023 improves lupus nephritis in Mrl/Lpr mice publication-title: BioMed Pharmacother doi: 10.1016/j.biopha.2022.113433 – volume: 26 year: 2015 ident: B48 article-title: Complement factor C4d is a common denominator in thrombotic microangiopathy publication-title: J Am Soc Nephrol doi: 10.1681/asn.2014050429 – volume: 344 year: 2001 ident: B27 article-title: Complement. first of two parts publication-title: N Engl J Med doi: 10.1056/nejm200104053441406 – volume: 39 year: 2012 ident: B18 article-title: The association between the mannose-binding lectin codon 54 polymorphism and systemic lupus erythematosus: A meta-analysis update publication-title: Mol Biol Rep doi: 10.1007/s11033-011-1361-6 – volume: 21 start-page: 13 year: 2012 ident: B46 article-title: Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: A pilot study publication-title: Lupus doi: 10.1177/0961203311422093 – volume: 4 year: 1994 ident: B5 article-title: Renal vascular complications of systemic lupus erythematosus publication-title: J Am Soc Nephrol doi: 10.1681/asn.V481499 – volume: 71 year: 2019 ident: B22 article-title: European League against Rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus publication-title: Arthritis Rheum doi: 10.1002/art.40930 – volume: 6 year: 2016 ident: B13 article-title: Masp-3 is the exclusive pro-factor d activator in resting blood: The lectin and the alternative complement pathways are fundamentally linked publication-title: Sci Rep doi: 10.1038/srep31877 – volume: 40 year: 2021 ident: B40 article-title: Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis publication-title: Clin Rheum doi: 10.1007/s10067-020-05499-1 – volume: 21 year: 2022 ident: B39 article-title: Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2022.103072 – volume: 93 year: 2018 ident: B23 article-title: Revision of the international society of Nephrology/Renal pathology society classification for lupus nephritis: Clarification of definitions, and modified national institutes of health activity and chronicity indices publication-title: Kidney Int doi: 10.1016/j.kint.2017.11.023 – volume: 17 year: 2006 ident: B36 article-title: Factor h and atypical hemolytic uremic syndrome: Mutations in the c-terminus cause structural changes and defective recognition functions publication-title: J Am Soc Nephrol doi: 10.1681/asn.2005080868 – volume: 12 year: 2021 ident: B32 article-title: The spectrum of C4d deposition in renal biopsies of lupus nephritis patients publication-title: Front Immunol doi: 10.3389/fimmu.2021.654652 – volume: 21 start-page: 245 year: 2020 ident: B53 article-title: A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy publication-title: BMC Nephrol doi: 10.1186/s12882-020-01888-5 – volume: 15 start-page: R12 year: 2013 ident: B7 article-title: The spectrum of renal thrombotic microangiopathy in lupus nephritis publication-title: Arthritis Res Ther doi: 10.1186/ar4142 – volume: 22 year: 2011 ident: B45 article-title: Complement factor h deficiency accelerates development of lupus nephritis publication-title: J Am Soc Nephrol doi: 10.1681/asn.2010060647 – volume: 8 year: 2012 ident: B21 article-title: Stec-hus, atypical hus and ttp are all diseases of complement activation publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2012.195 – volume: 61 year: 2014 ident: B37 article-title: Are complement deficiencies really rare? overview on prevalence, clinical importance and modern diagnostic approach publication-title: Mol Immunol doi: 10.1016/j.molimm.2014.06.030 – volume: 207 start-page: 29 year: 2010 ident: B43 article-title: Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor d publication-title: J Exp Med doi: 10.1084/jem.20090633 – volume: 14 year: 2005 ident: B31 article-title: Factors associated with poor outcomes in patients with lupus nephritis publication-title: Lupus doi: 10.1191/0961203305lu2238oa – volume: 18 year: 2022 ident: B52 article-title: Treat-to-Target in systemic lupus erythematosus: Advancing towards its implementation publication-title: Nat Rev Rheum doi: 10.1038/s41584-021-00739-3 – volume: 196 year: 2016 ident: B14 article-title: Masp-1 and masp-2 do not activate pro-factor d in resting human blood, whereas masp-3 is a potential activator: Kinetic analysis involving specific masp-1 and masp-2 inhibitors publication-title: J Immunol doi: 10.4049/jimmunol.1501717 – volume: 24 year: 2013 ident: B9 article-title: The pathogenesis of lupus nephritis publication-title: J Am Soc Nephrol doi: 10.1681/asn.2013010026 – volume: 3 year: 2002 ident: B54 article-title: Eculizumab (Alexion) publication-title: Curr Opin Investig Drugs – volume: 19 year: 2010 ident: B47 article-title: Association between anti-Beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: A prospective study of 155 cases publication-title: Lupus doi: 10.1177/0961203310368409 – volume: 164 year: 2000 ident: B44 article-title: Modulation of renal disease in Mrl/Lpr mice genetically deficient in the alternative complement pathway factor b publication-title: J Immunol doi: 10.4049/jimmunol.164.2.786 – volume: 83 year: 2013 ident: B6 article-title: Inclusion of renal vascular lesions in the 2003 Isn/Rps system for classifying lupus nephritis improves renal outcome predictions publication-title: Kidney Int doi: 10.1038/ki.2012.409 – volume: 65 year: 2004 ident: B20 article-title: Effects of complement factor d deficiency on the renal disease of Mrl/Lpr mice publication-title: Kidney Int doi: 10.1111/j.1523-1755.2004.00371.x – volume: 46 year: 2019 ident: B28 article-title: Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy publication-title: J Rheum doi: 10.3899/jrheum.180773 – volume: 19 year: 2010 ident: B34 article-title: Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy publication-title: Lupus doi: 10.1177/0961203310376523 – volume: 2 year: 2018 ident: B49 article-title: Complement-mediated thrombotic microangiopathy associated with lupus nephritis publication-title: Blood Adv doi: 10.1182/bloodadvances.2018019596 – volume: 18 year: 1991 ident: B35 article-title: Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. gruppo italiano per lo studio Della nefrite lupica (Gisnel) publication-title: Am J Kidney Dis doi: 10.1016/s0272-6386(12)80885-7 – volume: 20 year: 2011 ident: B42 article-title: Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis publication-title: Lupus doi: 10.1177/0961203311415561 – volume: 10 year: 2015 ident: B15 article-title: Molecules great and small: The complement system publication-title: Clin J Am Soc Nephrol doi: 10.2215/cjn.06230614 – volume: 8 year: 2012 ident: B1 article-title: B-cell depletion in the treatment of lupus nephritis publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2012.141 – volume: 13 year: 2017 ident: B38 article-title: Redefining lupus nephritis: Clinical implications of pathophysiologic subtypes publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2017.85 – volume: 129 year: 2017 ident: B50 article-title: Thrombotic thrombocytopenic purpura publication-title: Blood doi: 10.1182/blood-2016-10-709857 – volume: 42 start-page: 19 year: 2020 ident: B25 article-title: Renal microvascular lesions in lupus nephritis publication-title: Ren Fail doi: 10.1080/0886022x.2019.1702057 – volume: 75 year: 1983 ident: B30 article-title: Prognostic factors in lupus nephritis. contribution of renal histologic data publication-title: Am J Med doi: 10.1016/0002-9343(83)90338-8 – volume: 76 year: 1997 ident: B29 article-title: Renal vascular lesions in lupus nephritis publication-title: Med (Baltimore) doi: 10.1097/00005792-199709000-00003 – volume: 12 year: 2021 ident: B57 article-title: Factor d inhibition blocks complement activation induced by mutant factor b associated with atypical hemolytic uremic syndrome and membranoproliferative glomerulonephritis publication-title: Front Immunol doi: 10.3389/fimmu.2021.690821 |
SSID | ssj0000493335 |
Score | 2.3761804 |
Snippet | The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement... ObjectiveThe pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1081942 |
SubjectTerms | alternative pathway complement Complement Factor B Complement Membrane Attack Complex - analysis Endothelial Cells - metabolism Humans Immunology lectin pathway Lectins lupus nephritis Lupus Nephritis - pathology Prognosis Retrospective Studies Thrombotic Microangiopathies - pathology thrombotic microangiopathy von Willebrand Factor |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9swEBalMOjLWLd289oOFfpWTB0p_qHHtiyUwfqUQt-EZMmrRyKHOF7JY__z3klOiMfYXvZqWbasO_m-k-6-I-TCcmtENVIxgFUejyvD4yLV4zhnrLBWAGj2SWHf77O7h_G3x_Rxp9QXxoQFeuAwcVeqBKMpFKAYAPMsZZjQwLWuxqXWAE8M_n0Tkew4Uz8D7uWcpyFLBrwwcVXV83kH_iBjGFYHrjsbWCJP2P8nlPl7sOSO9Zm8I2972Eivw3APyZ5178mbUEhy_YG8TJ-WzVw30ErnGGKn3I-6wWrDa-pzQwBQ0kXTLCnGY7mmrVvqywzRWbfoWuosyBTZjeivWlEfZu63DSlu6teOKmeoP1d3niec4pOf1ZpiVkTY0z0iD5Ov09u7uC-uEJdcFKu4AORSsRS-SxlbZhoTTLUueGVyk-kkswY8L12yES_w0BgMmRC4X5qqTKRg0fgx2XeNs58ItVmmVWGSCrnt8Zy2TIUCzxO65MrwIiKjzUTLsmcexwIYMwkeCApHeuFIFI7shRORy22fReDd-OvdNyi_7Z3Ime0vgCbJXpPkvzQpIucb6UtYY3hwopxtulayHGnZcnD9IvIxaMP2VRwgHMKgiOQDPRmMZdji6ifP4y1ywKZ58vl_DP6EHOCEYKDNiJ-S_dWys2cAl1b6i18Zr69AFPQ priority: 102 providerName: Directory of Open Access Journals |
Title | Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36582241 https://www.proquest.com/docview/2759957260 https://pubmed.ncbi.nlm.nih.gov/PMC9792970 https://doaj.org/article/ac0649a91601425286243bbf4cbb019d |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELamTUi8IH4TBpOReEOBxk6c-AFNAzEmpPG0Sn2z7NjZglqnJM2gj_znu3PSiqKBxEulNr9zdu_7znffEfLacWdllegYwCqP08ryuMhMGueMFc5JAM2hKOz8qzibpl9m2WyPbNodjS-wu5XaYT-paTt_-_P7-hgm_HtknOBv31X1YtED1WMMM-aAlcNf8gF4JoFk7HyE-98GNMx56LmZCJHGMJbToY7mL6fZ8VVB0v82HPpnOuVv_un0Prk3Akt6MoyEB2TP-YfkztBqcv2I_Lq4apuFaWArXWASnvaXdYP9iNc0VI8A5KTLpmkpZmz5pqs7GhoR0Xm_7DvqHVgd9Y_oda1pSEQPgUWKYf_aU-0tDSvvPiiJUzzzD72mWDcxRH0fk-npp4uPZ_HYfiEuuSxWcQHYpmIZPJe2rhQGS1CNKXhlcyvMRDgL3MyULOEFLiuDq5MSI6qZFjIDn8efkH3fePeMUCeE0YWdVKh-jyu5ZSY1cFM4JNeWFxFJNi9alaM2ObbImCvgKGgcFYyj0DhqNE5E3myPWQ7KHP_c-wPab7snqmqHH5r2Uo2TVOkSAJrUgJiBOLKMYfEMN6ZKS2PgVm1EXm2sr2AW4tKK9q7pO8VyFG7LgRxG5OkwGraX4gDyEChFJN8ZJzv3srvF11dB6VvmgF7zyfP_etRDche_Ys5Nwl-Q_VXbu5eAnFbmKEQc4PPzLDkKU-MGo4UZlw |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombotic+microangiopathy+mediates+poor+prognosis+among+lupus+nephritis+via+complement+lectin+and+alternative+pathway+activation&rft.jtitle=Frontiers+in+immunology&rft.au=Zhang%2C+Binshan&rft.au=Xing%2C+Guolan&rft.date=2022-12-13&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.1081942&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2022_1081942 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |